"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help ...

There are two diabetes medications that are also used for weight loss – Rybelsus and Ozempic. They both contain the same drug called Semaglutide, Rybelsus is an oral medication whereas Ozempic is an ...

Rybelsus (semaglutide) is a brand-name oral tablet that’s prescribed for type 2 diabetes. The cost of the drug with and without insurance can depend on several factors, such as whether Rybelsus has a ...

Kelly Anne is a deputy editor at Forbes Advisor overseeing the development of various initiatives, including newsletters, social media, and new content verticals. Previously, she worked as a senior ...

Novo Nordisk A/S is closing in on Eli Lilly in the GLP-1 market despite Ozempic declines. Click for this NVO stock update.

Bagsværd, Denmark, 29 March 2025 - Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...

Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs worldwide under brand names Ozempic ...

Eli Lilly LLY announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.